Helen Torley - Nov 26, 2025 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ James R. Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Nov 26, 2025
Transactions value $
-$1,141,925
Form type
4
Date filed
12/1/2025, 07:31 PM
Previous filing
Nov 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Torley Helen PRESIDENT AND CEO, Director C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO /s/ James R. Oehler, Attorney-in-Fact 2025-12-01 0001528185

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Gift $0 -25K -3.41% $0.00 709K Nov 26, 2025 Direct F1
transaction HALO Common Stock Options Exercise $134K +16.6K +2.34% $8.11 725K Dec 1, 2025 Direct F2
transaction HALO Common Stock Sale -$713K -10.4K -1.43% $68.51 715K Dec 1, 2025 Direct F2, F3
transaction HALO Common Stock Sale -$375K -5.4K -0.76% $69.44 709K Dec 1, 2025 Direct F2, F4
transaction HALO Common Stock Sale -$35.2K -500 -0.07% $70.36 709K Dec 1, 2025 Direct F2, F5
transaction HALO Common Stock Sale -$18.7K -261 -0.04% $71.60 709K Dec 1, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Options Exercise -$134K -16.6K -100% $8.11 0 Dec 1, 2025 Common Stock 16.6K $8.11 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents a bona fide gift to charity.
F2 The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.
F3 Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.160 to $70.100. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.160 to $70.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.